Abbott Laboratories
ABT
107.25−2.04 (−1.87%)Nov 12, 7:00 PM ET
Key stats
- Open
- 110.32
- Day high
- 110.78
- Day low
- 106.89
- Previous close
- 109.29
- Volume
- 9.96M
- VWAP
- 107.69
- 52-week high
- 132.03
- 52-week low
- 81.97
- Market cap
- 189.28B
- Shares out
- 1.73B
- Employees
- 115,000
- Listed
- 1949
About Abbott Laboratories
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
PHARMACEUTICAL PREPARATIONS · ABBOTT PARK, IL · abbott.com
Options · expiring Nov 13
Nov 12, 4:00 PM ET- Call open interest
- 3.4K
- Put open interest
- 2.9K
- Put/call
- 0.85
- At-the-money IV
- 33.6%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 110 put | 2.56 | Nov 12, 1:54 PM | 1.1K | 1.4K | — |
| 107 put | 0.70 | Nov 12, 3:38 PM | 263 | 160 | 33.9% |
| 111 call | 0.05 | Nov 12, 3:59 PM | 168 | 251 | 62.3% |
| 110 call | 0.10 | Nov 12, 3:51 PM | 123 | 205 | 42.0% |
| 108 put | 1.25 | Nov 12, 3:54 PM | 116 | 192 | 35.6% |
| 112 put | 3.67 | Nov 12, 3:14 PM | 79 | 361 | — |
Quarterly results
Massive · Nov 4, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $13.01B | $12.59B | $11.16B | $11.46B |
| Gross profit | $7.38B | $7.27B | $6.27B | $6.54B |
| Operating income | $1.36B | $1.69B | $1.34B | $2.25B |
| Net income | $920.00M | $928.00M | $1.08B | $1.78B |
| Diluted EPS | 0.53 | 0.53 | 0.61 | 1.03 |
| Operating cash flow | $1.74B | $2.49B | $1.31B | $3.31B |
| Assets | $108.25B | $109.22B | $110.43B | $86.71B |
| Liabilities | $56.62B | $57.45B | $57.73B | $33.94B |
| Equity | $51.62B | $51.76B | $52.70B | $52.77B |
Technicals
Massive · Nov 12, 2026- 50-day average103.91
- 200-day average101.54
- RSI (14 days)51.4
Short interest
Massive · Oct 30, 2026- Oct 30, 202619.06M shares · 1.9 days to cover
- Oct 15, 202617.39M shares · 1.8 days to cover
- Sep 30, 202613.63M shares · 1.5 days to cover
- Sep 15, 202619.91M shares · 2.6 days to cover
Dividends
Massive · Oct 15, 2026- Ex Oct 15, 2026, paid Nov 16, 20260.6300 · 4 a year
- Ex Jul 15, 2026, paid Aug 17, 20260.6300 · 4 a year
- Ex Apr 15, 2026, paid May 15, 20260.6300 · 4 a year
- Ex Jan 15, 2026, paid Feb 13, 20260.6300 · 4 a year
- Ex Oct 15, 2025, paid Nov 17, 20250.5900 · 4 a year
- Ex Jul 15, 2025, paid Aug 15, 20250.5900 · 4 a year
- Ex Apr 15, 2025, paid May 15, 20250.5900 · 4 a year
- Ex Jan 15, 2025, paid Feb 14, 20250.5900 · 4 a year
Related companies
MassiveNews coverage
No stories about Abbott Laboratories right now.